Latest UPWORK'S Task!

Client: Ichorbio Website

Task 1: How to Deplete CD4+ T Cells in vivo

1. Introduction

T cells play a crucial role in advancing the broad field of immunological research, particularly $CD4^+$ T cells. A practical method is T cell depletion in vivo, which has effectively stimulated numerous immune response and their applications in disease recovery [1, 2]. There are many ways to support this technique, but the anti-CD4 antibody clone, GK1.5, is operative mainly because of its efficiency and specificity [3]. This review will discover the basic concept of in vivo T cell depletion, the benefits and limitations of GK1.5, other clones for several animal models, and current studies of GK1.5.

2. Understanding CD4+ T Cell Depletion

Targeting CD4+ T cells with the GK1.5 monoclonal antibodies is essential in understanding the immune responses, functions, and disease progression. Besides, CD4+ T cell depletion in vivo offers significant perceptions of cancer immunotherapy, autoimmune diseases, and infectious diseases [4, 5].

Mechanism of action of GK1.5

Primarily, the mouse CD4 antigen binds with the monoclonal antibody GK1.5. Interacting with TCR (T cell receptor), this antigen with 55 kDa cell surface type I membrane glycoprotein functions as a co-receptor. It also cooperates with antigen-presenting cells' class II MHC molecules. However, CD4 is essential for matured T cells to perform successfully and contributes to T cell advancement. This antibody's interrelation with CD4 provides high efficiency and specificity for T cell depletion in vivo on the T cell surface without disturbing other immune functions [5, 6, 7]. Due to its specialization, researchers can precisely analyze how CD4+ T cells act in immunological responses and the pathophysiology of diseases.

Drawbacks to consider

Despite its benefits, using GK1.5 requires caution. Off-target effects, where the antibody may bind to unintended cell types expressing CD4, can lead to nonspecific depletion or undesired immunological consequences [8]. Moreover, variations in experimental conditions, such as dosage and administration protocols, can affect the efficacy and specificity of GK1.5-mediated T cell depletion. Thus, careful optimization and validation of experimental parameters are crucial.

Determining the Dose of GK1.5

The optimal dose of GK1.5 can vary depending on the specific experimental requirements and animal model used. Generally, doses ranging from 50 to 500 μg per injection have been reported in literature for in vivo T cell depletion studies using GK1.5. Researchers should conduct dose-response experiments to determine the most effective dose for their particular setup, considering factors such as the age, strain, and health status of the animals, as well as the duration and frequency of antibody administration.

3. Alternative Clones for Different Animal Models

In addition to GK1.5, several alternative clones of anti-CD4 antibodies are available for different animal models:

Rat Models: Clone W3/25 is commonly used for T cell depletion in rats, offering comparable efficacy and specificity to GK1.5.

Non-Human Primate Models: Clone OKT4A is utilized for CD4+ T cell depletion in non-human primates with notable success.

Mouse Models: Clone YTS 191.1 is another alternative used in mice for depleting CD4+ T cells.

4. Recent studies on CD4+ T Cell Depletion Utilizing GK1.5

Clausen et al. (2022) demonstrated that a murine model of autoimmune arthritis significantly decreases disease severity upon GK1.5-mediated CD4+ T cell depletion. It stimulates therapeutic potential by reducing cytokine production and attenuating joint injury [9].

Another study by Euler and Alter (2015) described a murine model of HIV infection in which therapy with GK1.5 antibodies meaningfully reduces viral load and the duration of disease development [10].

According to Phadke et al. (2023), combined treatments like GK1.5 AND CTLA-4 antibodies improve antitumor immunity in a mouse melanoma model by targeting CD4+ and regulatory T cells. Then, depleted regulatory T cells increase responses by effector T cells and enhance the regulation of tumors during cancer immunotherapy [11].

5. Conclusion

In vivo T cell depletion using antibodies such as GK1.5 is a powerful approach to investigate the role of CD4+ T cells in health and disease. Understanding its advantages, pitfalls, dosage considerations, and recent research findings allows researchers to design experiments effectively

and advance our knowledge of immune function and therapeutic interventions. By exploring alternative clones for different animal models, researchers can further optimize their studies and achieve reliable, reproducible results.

6. References

1. Kervevan J, Chakrabarti LA. Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions. Int J Mol Sci. 2021 Jan 7;22(2):523.
2. Chatzileontiadou DSM, Sloane H, Nguyen AT, Gras S, Grant EJ. The Many Faces of $CD4^+$ T Cells: Immunological and Structural Characteristics. Int J Mol Sci. 2020 Dec 23;22(1):73.
3. Freise AC, Zettlitz KA, Salazar FB, Lu X, Tavaré R, Wu AM. ImmunoPET Imaging of Murine $CD4^+$ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. Mol Imaging Biol. 2017 Aug;19(4):599-609.
4. Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023 Jun 19;8(1):235.
5. Freise AC, Zettlitz KA, Salazar FB, Lu X, Tavaré R, Wu AM. ImmunoPET Imaging of Murine $CD4^+$ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. Mol Imaging Biol. 2017 Aug;19(4):599-609.
6. https://bioxcell.com/invivomab-anti-mouse-cd4-be0003-1 [Extracted information on June 29, 2024]
7. https://www.thermofisher.com/antibody/product/CD4-Antibody-clone-GK1-5-Monoclonal/14-0041-82 [Extracted information on June 29, 2024].
8. Mandel TE, Dillon H, Koulmanda M. The effect of a depleting anti-CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Transpl Immunol. 1995 Sep;3(3):265-72.
9. Clausen AS, Christensen C, Christensen E, Cold S, Kristensen LK, Hansen AE, Kjaer A. Development of a ^{64}Cu-labeled $CD4^+$ T cell targeting PET tracer: evaluation of CD4 specificity and its potential use in collagen-induced arthritis. EJNMMI Res. 2022 Sep 16;12(1):62.
10. Euler Z, Alter G. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res Hum Retroviruses. 2015 Jan;31(1):13-24.
11. Phadke MS, Li J, Chen Z, Rodriguez PC, Mandula JK, Karapetyan L, Forsyth PA, Chen YA, Smalley KSM. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models. J Immunother Cancer. 2023 Dec 6;11(12): e007239.

Task 2: Understanding PD-1 Blockade in Infectious Diseases

Introduction

The immune checkpoint receptor PD-1 (programmed cell death protein 1) preserve immunological homeostasis and avoids autoimmune disorders by regulating the apoptosis of T cells. The pdcd-1 gene in T and B cells, encodes PD-1 (CD279) in humans. It reduces T cell and cytokine production

through binding with ligands PD-L1 or PD-L2 (programmed death-ligand 1/2) to block the signaling of T cell receptors [1, 2]. As a result, several infectious diseases (caused by viruses, bacteria, fungi, and parasites), including HIV (Human immunodeficiency virus), COVID-19, and Dengue, are observed, however the cycle of T-cell damage is crucial for blocking autoimmunity [3].

How to work PD-1 blockade in infectious diseases

Recent studies have demonstrated that blocking PD-1 stimulates functional T-cell production in the immune system. These cells proliferate cytokine induction activating virus-specific CD8+ cells, ultimately leading to T cell exhaustion and viral control in HIV and HBV (Hepatitis B virus) [4]. Velu et al. reported that high PD-1 expression on HIV-specific CD8+ T cells correlated with reduced proliferative capacity and increased apoptosis. Anti-PD-1 agents enhanced these cells' ability to proliferate and produce key cytokines like IFN-γ and TNF-α [5]. Moreover, PD-1 blockade also improves HBV-specific T cell responses in chronic HBV, leading to enhance IL-2 production by HBV-specific T cells correlated with improved functionality and viral control post-PD-1 blockade [6, 7].

Reduction of viral load

Frequent studies reported that PD-1 blockade decreases viral load, which is investigated in HIV, HBV, and SIV (simian immunodeficiency virus) chronic viral infections. Another research demonstrated that PD-1 inhibitors strengthen the immune response and regulate chronic infections by reducing viral tanks.

Velu et al.'s experiment illustrated that the antibody PD-1 inhibitor (clone EH12.2H7) treats SIV-infected macaques after antiretroviral therapy (ART), leading to viral load reduction and CD8+ T cell improvement [8]. Another study indicated that viral load reduction is associated with increased T cell and IL-2 production after administrating anti-PD-1 agents in chronic HBV patients [6].

Potential combination therapies

Many studies highlight the potential of combining PD-1 blockade with other therapeutic agents to achieve synergistic effects. This approach can amplify the immune response and target different aspects of viral pathogenesis.

PD-1 inhibitors combine with latency-reversing chemicals, such as Bryostatin, leading to promising outcomes in the clearance of latent viruses during recent HIV research [9]. A study reported by Jubel et al. describes the combination therapy of vaccines (immunomodulatory medications) and anti-PD-1 agents to induce medicinal efficacy [10].

Exploring new approaches

The consistency of these findings across different viral models suggests broader applications for PD-1 blockade. Scientists investigate several viral infections, such as HBV and HIV, for PD-1 inhibition activity. PD-1 blockade therapy can also be targeted for the immune studies in EBV (Epstein-Barr virus or CMV (Cytomegalovirus) [11]. Additionally, the effect of PD-1 inhibition in co-infections (HIV and Tuberculosis) in the immune landscape. By enhancing T cell responses, PD-1 blockade could help manage co-infections more effectively, addressing a significant challenge in global health [12].

Practical considerations

For researchers embarking on PD-1 blockade studies, optimizing experimental conditions, including antibody handling, dosing, and timing, is essential. Consistency in these parameters ensures reproducibility and comparability across studies. Immune responses must be monitored carefully to avoid potential adverse effects, such as hyper-activation leading to immunopathology [13].

Conclusion

Several studies frequently demonstrated that anti-PD-1 agents (PD-1 blockade) efficiently increase T cell activation, reduce viral load, and are used in combination therapies to prevent chronic infectious illnesses. Therefore, by understanding these well-established applications, scientists can investigate various novel usages and therapeutic tactics to manage the advanced level of contagious ailments.

References:

1. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 2005 Aug 1;175(3):1586-92.

2. Bu MT, Yuan L, Klee AN, Freeman GJ. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):202- 209.

3. https://www.bcm.edu/departments/molecular-virology-and-microbiology/emerging-infections-and-biodefense/introduction-to-infectious-diseases [Extracted information on May 22, 2024]

4. Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap. 2015;6(1-2):7-17.

5. Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology. 2015 Feb 8; 12:14.

6. Chua C, Salimzadeh L, Ma AT, Adeyi OA, Seo H, Boukhaled GM, Mehrotra A, et al. IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B. Hepatol Commun. 2023 Dec 7;7(12): e0337.

7. Bertoletti A, Le Bert N. Immunotherapy for Chronic Hepatitis B Virus Infection. Gut Liver. 2018 Sep 15;12(5):497-507.

8. Velu V, Titanji K, Ahmed H, Shetty RD, Chennareddi LS, Freeman GJ, Ahmed R, Amara RR. PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques. Proc Natl Acad Sci U S A. 2022 Aug 16;119(33): e2202148119.

9. Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nat Commun. 2019 Feb 18;10(1):814.

10. Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The Role of PD-1 in Acute and Chronic Infection. Front Immunol. 2020 Mar 24; 11:487.

11. Baron M, Soulié C, Lavolé A, Assoumou L, Abbar B, Fouquet B, et al. The French Cooperative Thoracic Intergroup Ifct Chiva-Investigators, The Anrs Co OncoVIHAC Study Group. Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. Cells. 2022 Mar 17;11(6):1015.

12. Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018 Feb;18(2):91-104.

13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54

Task 3: Maximizing the potential of RMP1-14 in immuno-oncology and preclinical research

Introduction

The advancement of immune checkpoint blockers, including PD-1 inhibitors, has recently created a breakthrough in oncology-related immune disorders [1]. RMP1-14 has become a vital antibody in treating immune-oriented tumors and using it for therapeutic purposes; however, several anti-PD-1 agents are offered for preclinical studies [2]. In the review, we examine various approaches to RMP1-14 antibodies, particularly in animal studies and immuno-oncology treatments. It also underlines anti-PD-1's role in cancer medications and induces extensive research for further potential therapies.

RMP1-14 in Cancer Immunotherapy Models

The principal feature of RMP1-14 is its well-known efficacy in numerous cancer models with preclinical investigations. According to a recent study, PD-1 inhibitors show outstanding results by upregulating immune responses and increasing the survival rate of 4T1 breast cancer, B16 melanoma, and MC38 colon carcinoma patients [3].

To discover possible synergistic effects and design for advanced drugs, RMP1-14 can combine with additional immunotherapies, such as CTLA-4 inhibitors (anti-CTLA-4 clone 9H10) to activate T cells and regress tumor formation, which can interact with RMP1-14 in different preclinical studies. Another study demonstrated that RMP1-14 can combine with adoptive cell therapies, targeted therapies, and cancer vaccines to explore potential effectiveness against carcinogenesis [4, 5].

Investigating Mechanisms of Action and Resistance

RMP1-14 has become a powerful tool for understanding the anti-tumor activity of PD-1 blockade and its resistance pathways as medicinal aspects. Based on its preclinical results, scientists have learned the effects of PD-1 signaling on T-cells differentiation, stimulation, and exhaustion in multiple approaches [6].

Moreover, it is being used to investigate the impacts of PD-1 inhibitors on cytokine production, immune cell infiltration, and immunosuppressive cell populations inside the tumor microenvironment. Through these understandings, researchers have gained insights into how PD-1 blockade controls tumor cells, immune cells, and the stromal constituents complex, leading to anti-tumor activity [7].

It has also studied how PD-1 inhibitors become resistant by losing tumor antigen expression, developing immunosuppressive signals, and inducing alternative immune checkpoints. These investigative outcomes help manufacture anti-resistant drugs and trigger the effects of PD-1-targeted medications by finding potential biomarkers and their mechanisms [8, 9].

Translational Insights from RMP1-14 Studies

The main objective of preclinical research is to learn translational perceptions, which direct the creation of clinical policies and concerns about patient carefulness. In the area of immune-oriented cancer biology, RMP1-14 has significantly covered the gap in knowledge between fundamental research and clinical applications.

The RMP1-14 preclinical research has insightfully compared to PD-1 blockades in clinical studies, including Pembrolizumab and Nivolumab, which authorize mouse models and identify ideal therapies for human trials. This gathered information is based on the RMP1-14 guide to design combined therapies, find potential collaborators, and standard dosage plans for clinical studies [10, 11].

It has also been implemented to explore possible biomarkers and predictors of immune cell filtration, tumor mutational load, and PD-L1 expression as responses to PD-1 inhibitors. These studies have informed patient selection and stratification approaches for clinical trials and identify subpopulations most likely to benefit from PD-1-targeted therapies [12].

Expanding Outside Immuno-Oncology

While RMP1-14 has been primarily used in immuno-oncology, its applications extend beyond cancer research. The antibody has been employed to investigate the role of PD-1 in various other disease settings, such as infectious diseases, autoimmunity, and transplantation [13].

The RMP1-14 antibody has studied how the PD-1 signal affects T-cell exhaustion and how PD-1 inhibitors boost anti-immunity in various infectious diseases. These investigations have offered a complete understanding of PD-1's contribution to chronic contagious illness, including hepatitis C, and HIV, and how anti-PD-1 agents prevent viral infection, leading to disease suppression [14].

Studies reported that the PD-1 protein also triggers several autoimmune ailments, including lupus, multiple sclerosis, and rheumatoid arthritis. So, scientists found positive results by applying RMP1-14 as an anti-PD-1 drug in these diseases, regulating immune resistance and blocking unnecessary inflammation [15]. Moreover, RMP1-14 has been applied to the field of transplantation, where PD-1 signaling plays a critical role in regulating alloimmune responses and promoting graft tolerance. Preclinical studies using RMP1-14 have provided valuable insights into the potential of PD-1 blockade to prevent graft rejection and modulate graft-versus-host disease, informing the development of novel immunomodulatory strategies for transplant recipients [16].

Conclusion

RMP1-14 has emerged as a versatile and powerful tool for investigating the role of PD-1 in immuno-oncology and preclinical research. From its proven efficacy in cancer immunotherapy models to its applications in elucidating mechanisms of action and resistance, RMP1-14 has made significant contributions to our understanding of PD-1 biology and its therapeutic potential.

Following its experimental studies, the RMP1-14 antibody will promote the advancement of running oncology-immune-associated drugs and lead to clinical usages from preclinical discoveries. Consequently, researchers found that RMP1-14 administration enhances combined new medications, redesigns medicinal policies, and improves potential methods by preventing drug resistance. Furthermore, its possible implementations have extended outside the oncology areas, with significant outcomes in transplantation, autoimmunity, and infectious diseases. It also explores the complexity of these illnesses and the depth of immune checkpoints.

Ultimately, the story of RMP1-14 highlights the importance of basic research in driving clinical progress and the critical role of preclinical models in bridging the gap between bench and bedside. As we continue to invest in the development and application of powerful tools like RMP1-14, we

can unlock new insights into the complexities of the immune system and develop more effective strategies for harnessing its power to fight disease.

Are you seeking reasonable, high-quality RMP1-14 antibodies to further your research? Ichorbio has an extensive reputation for providing various stages of high-grade RMP1-14 antibodies, such as low endotoxin, ultra-low endotoxin, extremely low endotoxin, murine versions, and Fc (fragmented crystallizable region) silenced versions.

References:

1. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr 24;29(5):3044-3060.
2. Bernardo M, Tolstykh T, Zhang YA, Bangari DS, Cao H, Heyl KA, Lee JS, et al. An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy. Oncoimmunology. 2021 Mar 16;10(1):1881268.
3. Zhai Y, Dong S, Li H, Zhang Y, Shami P, Chen M. Antibody-mediated depletion of programmed death 1-positive (PD-1^{+}) cells. J Control Release. 2022 Sep; 349:425-433.
4. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021 Jun;11(6):1368-1397.
5. Oliveira LJC, Gongora ABL, Jardim DLF. Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Curr Oncol Rep. 2020 Jun 12;22(7):70.
6. Agrawal K, Hill RC, Wilkinson BL, Allison PB, Thomas CE. Quantification of the anti-murine PD-1 monoclonal antibody RMP1-14 in BALB/c mouse plasma by liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study. Anal Bioanal Chem. 2020 Jan;412(3):739-752.
7. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 2012 Oct 15;72(20):5209-18.
8. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018 Jan/Feb;24(1):47-53.
9. Wang L, Yang Z, Guo F, Chen Y, Wei J, Dai X, Zhang X. Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer. Front Immunol. 2023 Jul 3; 14:1227797.
10. Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017 Apr;44(2):136-140.
11. Berckmans Y, Ceusters J, Vankerckhoven A, Wouters R, Riva M, Coosemans A. Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy. Front Immunol. 2023 Sep 7; 14:1236965.
12. Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022 Jun;126(12):1663-1675.

13. Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, Jiang L, Dai XM, Chen WQ, Lin Q, Li XZ. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023 May 16; 14:1163633.
14. Zinselmeyer BH, Heydari S, Sacristán C, Nayak D, Cammer M, Herz J, Cheng X, Davis SJ, Dustin ML, McGavern DB. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med. 2013 Apr 8;210(4):757-74.
15. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742.
16. Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007 Oct 15;179(8):5204-10.

Task 4: Belantamab: A Comprehensive Overview

1. Background study

In both relapsed and refractory categories, patients with multiple myeloma (MM), a blood malignancy, do not show any improvement or at least a minor response after sixty days of starting treatment [1]. With an occurrence of 4.5 to 6 per 100,000 yearly, MM accounts for 1.8% of all new cancer cases and 2.1% of all cancer-related deaths in the United States each year [2]. MM presently has 160,000 cases and a 106,000 fatality rate globally [3]. Although it is typically incurable, survival rates have increased over the past few decades due to new treatment development [4]. When treating MM, Belantamab mafodotin, a monoclonal antibody treatment, has demonstrated significant effectiveness and safety [5].

2. Target and its mechanism

Targeting B-cell maturation antigen (BCMA) protein, which is expressed on the myeloma cell surface, Belantamab mafodotin as an earlier ADC (Antibody-drug conjugate) that works against BCMA in the MM management [6]. It coupled with MMAF (Monomethyl auristatin F), a solid microtubule-disrupting factor, results in cell death [7]. After binding with BCMA, Belantamab induces ADCC (Antibody-dependent cellular cytotoxicity) and ADCP (Antibody-dependent cellular phagocytosis) by inhibiting BCMA receptor signaling and microtubule polymerization [8,9].

3. Medicinal usages

Belantamab was the first targeted antibody therapy approved by the FDA in 2020 for treating relapsed or refractory myeloma in adult patients, even though some medications, such as

immunomodulatory drugs, protease inhibitors, and anti-CD38 monoclonal antibodies, have already used [10].

4. Clinical study results

According to Lonial et al., Belantamab reported a total rate of 32% positive response and an average treatment period of 11 months with MM patients who were previously pretreated during the phase II DREAMM-2 trial [11]. Comparing Belantamab to Pomalidomide and dexamethasone (low-dose), recent clinical studies demonstrated significant progress in survival incidence during the phase III DREAMM-3 trial [12, 13].

5. Side effects

Patients-administered Belantamab shows some frequent side effects, such as reduced platelets, corneal illness, diminished vision, anemia, pyrexia, and fetal danger [7]. According to the toxicity profile, eye toxicity affected 44% of patients and reported 33.3% of patients associated with keratopathy grade 2-3 (Fluctuations in visual acuteness) [14, 15].

6. Molecular engineering and development

Belantamab has been manufactured using a humanized anti-BCMA antibody technique, conjugating MMAF through a non-cleanable linker [5]. The drug-and-antibody ratio is 4:1 [16].

7. Potential drug interactions

Other medications, including OATP (Organic anion transporting polypeptide) and P-glycoprotein (P-gp) transporters-oriented drugs, also collaborated with Belantamab in treating MM [7]. However, combined dose of Belantamab with CYP3A4 inhibitors may raise the likelihood of adverse side effects [17].

8. New prospective uses

It is also studied with several drugs, such as Lenalidomide, Bortezomib, and Pembrolizumab, in treating multiple myeloma [11, 13]. Additionally, Belantamab is also being investigated as a possible medication for BCMA-expressing malignancy treatment [14].

9. Other antibodies in clinical development

Despite Belantamab, numerous other anti-BCMA agents, such as AMG 701, CC-99712, and MEDI2228 are being studied clinically for MM treatment [19]. Although the mechanisms of

action of many medicines are similar, their pharmacokinetic properties and safety issues may vary [20].

10. References

1. Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023 Feb 15;30(2):2322-2347.

2. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021 Jan 20;9(1).

3. Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020 Sep;25(9): e1406-e1413.

4. clinicaltrials.gov/study/NCT03514121 [Extracted information on 28 April 2024]

5. Morè S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers (Basel). 2023 May 27;15(11):2948.

6. Matula Z, Uher F, Vályi-Nagy I, Mikala G. The Effect of Belantamab Mafodotin on Primary Myeloma-Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells. Int J Mol Sci. 2023 Mar 10;24(6):5303.

7. Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, Kaye AD, Varrassi G, Viswanath O, Urits I. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Curr Oncol. 2021 Jan 21;28(1):640-660.

8. Fu Z., Li S., Han S., Shi C., Zhang Y. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. *Signal Transduct. Target. Ther.* 2022; 7:93. doi: 10.1038/s41392-022-00947-7.

9. Martino, E. A., Bruzzese, A., Iaccino, E., Labanca, C., Mendicino, F., Mimmi, S., … Gentile, M. (2023). Belantamab mafodotin in multiple myeloma. *Expert Opinion on Biological Therapy*, *23*(11), 1043–1047.

10. Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, Ma L, Okusanya OO, Simpson NE, Nguyen W, Theoret MR, Pazdur R, Gormley NJ. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022 Nov 1;28(21):4629-4633.

11. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.

12. Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10): e801-e812.

13. Trudel, S., McCurdy, A., Louzada, M.L. *et al.* Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. *Nat Med* **30**, 543–551 (2024).

14. Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, et al. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma. Int J Mol Sci. 2023 Jul 23;24(14):11829.

15. Popat R, Warcel D, O'Nions J, Cowley A, Smith S, Tucker WR, Yong K, Esposti SD. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020 May;105(5): e261-e263.

16. Xing L, Liu Y, Liu J. Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy. Cancers (Basel). 2023 Apr 11;15(8):2240.

17. Iida S, Sunami K, Mishima Y, Fujii T, Kato H, Terao T, Matsuzawa Y, Matsubara M, Crossman T, Kremer BE, Gupta I. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11. Int J Hematol. 2023 Nov;118(5):596-608.

18. de la Rubia J, Alonso R, Clavero ME, Askari E, García A, Antón C, Fernández M, Escalante F, García A, et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers (Basel). 2023 May 29;15(11):2964.

19. Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, Bocchia M, Gozzetti A. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023 Mar 22;6(1):169-181.

20. Chang HP, Le HK, Shah DK. Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes. Pharmaceutics. 2023 Apr 3;15(4):1132.